Artisan Partners Limited Partnership Takes Position in Guardant Health, Inc. (NASDAQ:GH)

Artisan Partners Limited Partnership acquired a new position in Guardant Health, Inc. (NASDAQ:GH) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 49,065 shares of the company’s stock, valued at approximately $1,499,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Lord Abbett & CO. LLC purchased a new stake in Guardant Health in the third quarter valued at approximately $15,624,000. Guyasuta Investment Advisors Inc. acquired a new position in Guardant Health during the 4th quarter worth about $206,000. Geode Capital Management LLC grew its position in Guardant Health by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock valued at $64,754,000 after acquiring an additional 29,686 shares in the last quarter. Entropy Technologies LP acquired a new stake in shares of Guardant Health during the fourth quarter worth about $377,000. Finally, Pier Capital LLC grew its holdings in shares of Guardant Health by 36.7% in the third quarter. Pier Capital LLC now owns 158,429 shares of the company’s stock valued at $3,634,000 after purchasing an additional 42,575 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Trading Down 4.5 %

GH stock opened at $43.14 on Friday. The business has a 50 day simple moving average of $44.66 and a 200-day simple moving average of $34.30. The company has a market capitalization of $5.32 billion, a P/E ratio of -12.12 and a beta of 1.50. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $50.89.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The business had revenue of $201.81 million for the quarter, compared to analysts’ expectations of $192.50 million. Research analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on GH shares. Guggenheim reissued a “buy” rating and issued a $56.00 price target on shares of Guardant Health in a research report on Monday, February 24th. Scotiabank boosted their target price on Guardant Health from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research note on Monday, February 24th. JPMorgan Chase & Co. increased their price target on Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Stifel Nicolaus boosted their price objective on Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Finally, Barclays began coverage on shares of Guardant Health in a report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 price target for the company. Twenty equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $48.95.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.